Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection.
about
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trialThe impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysisInvestigative pathology: leading the post-genomic revolutionUtility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus StatementMolecular Mechanisms of Bone Metastasis: Which Targets Came from the Bench to the Bedside?Towards decision-making using individualized risk estimates for personalized medicine: A systematic review of genomic classifiers of solid tumors.Use of Gene Expression Profiling and Chemotherapy in Early-Stage Breast Cancer: A Study of Linked Electronic Medical Records, Cancer Registry Data, and Genomic Data Across Two Health Care Systems.Genomic Grade Index (GGI): feasibility in routine practice and impact on treatment decisions in early breast cancerPrognostic value of gene signatures and proliferation in lymph-node-negative breast cancerAdjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10).Uptake of a 21-gene expression assay in breast cancer practice: views of academic and community-based oncologists.Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer.Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study.RARRES3 suppresses breast cancer lung metastasis by regulating adhesion and differentiationTumor gene expression profiling in women with breast cancer. Test category: prognostic.Using patient management as a surrogate for patient health outcomes in diagnostic test evaluationProspective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer.Is the 21-gene recurrence score a cost-effective assay in endocrine-sensitive node-negative breast cancer?Impact of Oncotype DX on treatment decisions in ER-positive, node-negative breast cancer with histologic correlation.Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer.Physician survey of the effect of the 21-gene recurrence score assay results on treatment recommendations for patients with lymph node-positive, estrogen receptor-positive breast cancer.Emerging gene-based prognostic tools in early breast cancer: First steps to personalised medicine.Association between genomic recurrence risk and well-being among breast cancer patients.The EndoPredict Gene-Expression Assay in Clinical Practice - Performance and Impact on Clinical DecisionsJumping on the Train of Personalized Medicine: A Primer for Non- Geneticist Clinicians: Part 3. Clinical Applications in the Personalized Medicine Area.US Insurance Program's Experience With a Multigene Assay for Early-Stage Breast Cancer.The role of epigenetics in personalized medicine: challenges and opportunities.The effects of X-ray irradiation on the proliferation and apoptosis of MCF-7 breast cancer cells.Why does Oncotype DX recurrence score reduce adjuvant chemotherapy use?The value of personalizing medicine: medical oncologists' views on gene expression profiling in breast cancer treatmentThe clinical impact of 21-gene recurrence score on treatment decisions for patients with hormone receptor-positive early breast cancer in Korea.Review of the clinical studies using the 21-gene assay.Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence scoreImpact of multigene assays in early stage breast cancer.The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists.Economic Impact of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in France.Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH StudyGene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancerPrediction and prognosis: impact of gene expression profiling in personalized treatment of breast cancer patients
P2860
Q24597456-91A96BA1-2605-4619-B144-1B1040411DB6Q26861418-3B497755-7A40-44D0-B221-E151AF1CD899Q27002945-EEB90969-822D-49B6-B63A-1FE40FC1E0D4Q27020973-E5162B5B-134D-4F20-A9AF-7B4E47F31D76Q28068956-B61B6CFF-FB07-413D-8627-25C679A539C0Q30252422-DE821636-7110-4283-AB8C-0D884D5F769AQ31101528-633A0696-DCEC-4E1C-8F7B-F00241D6201BQ31130084-F303E392-56F2-4421-A6D1-B7D1D92606B8Q31152670-BBE79AA4-A456-4035-92ED-290406A33AA0Q33560459-15BB8ECD-173F-4A2D-A2A9-B386FB4ABA94Q33611159-E99DD665-E661-4DA2-8F2C-2C17A1DB9710Q33766513-F00F54EF-55AC-42AB-984B-2E78A78472AAQ33915023-8B0EABEF-F81A-443A-B445-DD72670834CAQ33991449-A9CBEC39-1B18-44AF-8D56-65DDFF746B99Q34130881-947534DB-D0D8-4C60-8F7F-5500C4467C4AQ34158661-94238F31-92ED-4438-93CB-B0BFF7440694Q34190743-CD81B035-B8EF-4EA7-84EA-7EAB6F7B70FFQ34338152-C1194E01-17DB-4C46-BF25-D1ECD38762A3Q34341066-B635CB34-7B4B-420E-B5C9-A2112955EB73Q34431985-FBB9C649-97D2-45FB-ADBD-545BAF1C19D5Q34638067-CAC45245-225D-49FC-986A-9E5F8B5FB088Q34657656-B281C845-9430-4DD2-8B25-8D567C536248Q34777432-6FC5351B-C032-482E-8278-1B6E24D42C15Q34797928-47D1AA1E-6504-4E87-B7F5-244A9A08F780Q34879739-EB1E1F8D-93DF-4EDC-9AD4-41F0C27074C3Q34974208-7401B155-AE27-4712-8E96-B7C97E0C2A21Q35043066-415D11C7-AC6F-441D-8719-2C284BF80AF9Q35119586-1BD458AE-8496-4535-B9DF-15614C14E7ABQ35146930-435C392B-739B-4289-BFFF-21F1ADE95593Q35345599-BB0295A1-EA5E-4271-9F3C-BEB03B1B862EQ35430076-28300C1B-EFE8-4721-B558-1480241E48CAQ35584053-A829E8B5-2D30-4A11-A1AB-6606D167208EQ35584364-79847996-203D-45D8-83A6-96B09F609DE8Q35599759-5F39220C-75B8-4489-8346-8162E221CC44Q35599773-6F3B0C7E-6D40-4260-B65F-BF0AE610E874Q35667378-BB4336B5-FD46-4983-A914-9BB9094952A5Q35915708-885FB75E-395F-48FD-9C53-BEF03A3BA395Q36055953-2A206320-E2F7-4DD5-A08F-E27BF433B737Q36097503-6F6FCE7B-A3A0-4EEA-B559-CF7CD201B76AQ36117673-66F7F889-D120-47B6-BF53-E1549F55DC0B
P2860
Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Prospective multicenter study ...... st cancer treatment selection.
@ast
Prospective multicenter study ...... st cancer treatment selection.
@en
Prospective multicenter study ...... st cancer treatment selection.
@nl
type
label
Prospective multicenter study ...... st cancer treatment selection.
@ast
Prospective multicenter study ...... st cancer treatment selection.
@en
Prospective multicenter study ...... st cancer treatment selection.
@nl
prefLabel
Prospective multicenter study ...... st cancer treatment selection.
@ast
Prospective multicenter study ...... st cancer treatment selection.
@en
Prospective multicenter study ...... st cancer treatment selection.
@nl
P2093
P356
P1476
Prospective multicenter study ...... st cancer treatment selection.
@en
P2093
Andrew Epstein
Daniel F Hayes
Ellen R Gaynor
Helen K Chew
Jeffrey Smerage
John Norton
Joseph Kash
Karen Rychlik
Kathy S Albain
Patricia B Mumby
P304
P356
10.1200/JCO.2008.20.2119
P407
P577
2010-01-11T00:00:00Z